The partial government shutdown may have diminished staffing at the SEC, but it hasn’t dimmed the hopes of biotech firms hoping to go public. On Friday, Kaleido Biosciences and Cirius Therapeutics both filed paperwork for their respective initial public offerings with the securities regulator.
While it’s operating with “very limited staff” due to the shutdown, the SEC’s electronic system for regulatory filings is still up and running. Kaleido and Cirius join a handful of biotechs that have filed for IPOs since the shutdown started last month.
Kaleido, a microbiome drugs developer, set a preliminary $100 million target for its IPO. The… Read more »
UNDERWRITERS AND PARTNERS